Asset profile
Methotrexate
Unknown / undisclosed
Approvedregulatory verdict
Evidence outlook
Approved: Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Featured evidence outside covered markets:NCT00002456 · Graft Versus Host Disease · Phase 3 · completed · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Methotrexate: this drug | Approved | — | Dihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitor | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | ||
| HZT-501 (Duexis) | Approved | Small molecule | Cyclooxygenase (COX-1/COX-2) plus histamine H2 receptor | ||
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(147 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (29)
October 2026 (3)
Phase 4Psoriasis, PruritusNot yet recruiting
Est. primary completion 2026-10-14 · NCT07432386 · CT.gov ↗
What to watch
Early phase / not applicableChemotherapy Induced Oral MucositisNot yet recruiting
Est. primary completion 2026-10-30 · NCT07327476 · CT.gov ↗
What to watch
Phase 2T Acute Lymphoblastic Leukemia, T Lymphoblastic LymphomaRecruiting
Est. primary completion 2026-10-31 · NCT00501826 · CT.gov ↗
What to watch
November 2026 (9)
Phase 2CNS LymphomaNot yet recruiting
Est. primary completion 2026-11 · NCT06901999 · CT.gov ↗
What to watch
Phase 2Sickle Cell DiseaseActive not recruiting
Est. primary completion 2026-11 · NCT04018937 · CT.gov ↗
What to watch
Phase 3Moderate to Severe Atopic DermatitisRecruiting
Est. primary completion 2026-11 · NCT06239311 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2026-11-01 · NCT05519579 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaRecruiting
Est. primary completion 2026-11-01 · NCT02877303 · CT.gov ↗
What to watch
Early phase / not applicableMalignant Bone TumorRecruiting
Est. primary completion 2026-11-01 · NCT06302465 · CT.gov ↗
What to watch
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-11-07 · NCT07446400 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic Leukemia, PediatricActive not recruiting
Est. primary completion 2026-11-30 · NCT03020030 · CT.gov ↗
What to watch
Early phase / not applicableVitiligoNot yet recruiting
Est. primary completion 2026-11-30 · NCT06877455 · CT.gov ↗
What to watch
December 2026 (17)
Phase 2GVHD,Acute, Acute Leukemia, Myelodysplastic Syndromes, Myeloproliferative DisordersRecruiting
Est. primary completion 2026-12 · NCT06315309 · CT.gov ↗
What to watch
Phase 3Cardiac Sarcoidosis, SarcoidosisRecruiting
Est. primary completion 2026-12 · NCT03593759 · CT.gov ↗
What to watch
Phase 4Hand Osteoarthritis, Erosive OsteoarthritisActive not recruiting
Est. primary completion 2026-12 · NCT04579848 · CT.gov ↗
What to watch
Phase 1/2Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT06207123 · CT.gov ↗
What to watch
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT06387121 · CT.gov ↗
What to watch
Phase 4Depression, Anxiety, PsoriasisRecruiting
Est. primary completion 2026-12-01 · NCT07432815 · CT.gov ↗
What to watch
Early phase / not applicableChronic Plaque PsoriasisNot yet recruiting
Est. primary completion 2026-12-01 · NCT07581418 · CT.gov ↗
What to watch
Phase 2Leptomeningeal Metastasis of Breast CancerRecruiting
Est. primary completion 2026-12-13 · NCT06543992 · CT.gov ↗
What to watch
Phase 1Lymphoma, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT06475235 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-cell LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT05257018 · CT.gov ↗
What to watch
Phase 1/2Leptomeningeal Metastasis From Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT07559097 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04216524 · CT.gov ↗
What to watch
Phase 2Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia …Active not recruiting
Est. primary completion 2026-12-31 · NCT02981628 · CT.gov ↗
What to watch
Phase 3T-cell Lymphoblastic LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05681260 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisActive not recruiting
Est. primary completion 2026-12-31 · NCT05353829 · CT.gov ↗
What to watch
2027 (49)
January 2027 (3)
Phase 2Vulvar Lichen SclerosusRecruiting
Est. primary completion 2027-01 · NCT07352917 · CT.gov ↗
What to watch
Phase 2Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-01-15 · NCT06590090 · CT.gov ↗
What to watch
Phase 2Caesarean Scar PregnancyNot yet recruiting
Est. primary completion 2027-01-20 · NCT07288307 · CT.gov ↗
What to watch
February 2027 (3)
Phase 2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-02 · NCT05583071 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System LymphomaRecruiting
Est. primary completion 2027-02-13 · NCT06832267 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1 …Active not recruiting
Est. primary completion 2027-02-28 · NCT03147612 · CT.gov ↗
What to watch
March 2027 (4)
Phase 2Acute Lymphoblastic Leukemia, Philadelphia Chromosome-PositiveActive not recruiting
Est. primary completion 2027-03 · NCT04329325 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-03-01 · NCT03150693 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-03-05 · NCT07636057 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03-22 · NCT03710772 · CT.gov ↗
What to watch
April 2027 (6)
Early phase / not applicablePrimary Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2027-04 · NCT07406230 · CT.gov ↗
What to watch
Phase 1Primary Diffuse Large B-Cell Lymphoma of the Central Nervous SystemActive not recruiting
Est. primary completion 2027-04-01 · NCT04609046 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaActive not recruiting
Est. primary completion 2027-04-01 · NCT05303792 · CT.gov ↗
What to watch
Phase 1B Acute Lymphoblastic Leukemia, Ph-Like Acute Lymphoblastic LeukemiaActive not recruiting
Est. primary completion 2027-04-12 · NCT05157971 · CT.gov ↗
What to watch
Phase 2Rheumatoid ArthritisRecruiting
Est. primary completion 2027-04-15 · NCT07409103 · CT.gov ↗
What to watch
Phase 2Hematopoietic and Lymphatic System NeoplasmRecruiting
Est. primary completion 2027-04-30 · NCT06895473 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Polycythemia Vera (PV), Essential Thrombocythemia (ET), Myelofibrosis (MF)Recruiting
Est. primary completion 2027-06 · NCT06541249 · CT.gov ↗
What to watch
Phase 2Ectopic PregnancyNot yet recruiting
Est. primary completion 2027-06 · NCT07624903 · CT.gov ↗
What to watch
Phase 3Mature B-cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT03206671 · CT.gov ↗
What to watch
Phase 2Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT02427620 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Relapsing PolychondritisRecruiting
Est. primary completion 2027-07 · NCT06941376 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2NeuroblastomaNot yet recruiting
Est. primary completion 2027-08 · NCT05303727 · CT.gov ↗
What to watch
Phase 2LeukemiaActive not recruiting
Est. primary completion 2027-08 · NCT01920737 · CT.gov ↗
What to watch
Phase 3Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease SeverityActive not recruiting
Est. primary completion 2027-08-30 · NCT04483466 · CT.gov ↗
What to watch
September 2027 (4)
Early phase / not applicableLymphoma CnsRecruiting
Est. primary completion 2027-09-02 · NCT07191431 · CT.gov ↗
What to watch
Phase 2/3Renal Pelvis and Ureter Urothelial CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT04628767 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down SyndromeActive not recruiting
Est. primary completion 2027-09-30 · NCT03914625 · CT.gov ↗
What to watch
Phase 4PhenylketonuriaRecruiting
Est. primary completion 2027-09-30 · NCT07477691 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2Graft Versus Host Disease, Hematologic MalignancyRecruiting
Est. primary completion 2027-10-18 · NCT06252870 · CT.gov ↗
What to watch
Phase 2Primary Intraocular LymphomaRecruiting
Est. primary completion 2027-10-30 · NCT06973811 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia …Active not recruiting
Est. primary completion 2027-10-31 · NCT01424982 · CT.gov ↗
What to watch
November 2027 (3)
Phase 1Central Nervous System LymphomaActive not recruiting
Est. primary completion 2027-11 · NCT03684980 · CT.gov ↗
What to watch
Phase 4Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis, Alopecia Universalis (AU), Alopecia Totalis (AT) …Recruiting
Est. primary completion 2027-11-01 · NCT07381556 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein Expression …Recruiting
Est. primary completion 2027-11-30 · NCT03263572 · CT.gov ↗
What to watch
December 2027 (15)
Phase 2T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute LeukemiaRecruiting
Est. primary completion 2027-12 · NCT06390319 · CT.gov ↗
What to watch
Phase 4Juvenile Idiopathic ArthritisRecruiting
Est. primary completion 2027-12 · NCT06653634 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma TreatmentRecruiting
Est. primary completion 2027-12-01 · NCT06946407 · CT.gov ↗
What to watch
Phase 1B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia …Active not recruiting
Est. primary completion 2027-12-02 · NCT04872790 · CT.gov ↗
What to watch
Phase 2Precursor Cell Lymphoblastic Leukemia-LymphomaRecruiting
Est. primary completion 2027-12-15 · NCT05660473 · CT.gov ↗
What to watch
Phase 1/2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …Recruiting
Est. primary completion 2027-12-25 · NCT01371630 · CT.gov ↗
What to watch
Phase 4Autoimmune Rheumatic DiseasesRecruiting
Est. primary completion 2027-12-30 · NCT07242092 · CT.gov ↗
What to watch
Phase 1NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT03719105 · CT.gov ↗
What to watch
Phase 2Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia …Active not recruiting
Est. primary completion 2027-12-31 · NCT05761171 · CT.gov ↗
What to watch
Phase 2Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative NeoplasmRecruiting
Est. primary completion 2027-12-31 · NCT03970096 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2027-12-31 · NCT06913907 · CT.gov ↗
What to watch
Phase 4Psoriatic Arthritis (PsA)Recruiting
Est. primary completion 2027-12-31 · NCT07486843 · CT.gov ↗
What to watch
Early phase / not applicableImmunoclassification, PsoriasisRecruiting
Est. primary completion 2027-12-31 · NCT05503875 · CT.gov ↗
What to watch
2028 (38)
January 2028 (4)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Non Hodgkin Lymphoma (NHL)Not yet recruiting
Est. primary completion 2028-01-01 · NCT06646211 · CT.gov ↗
What to watch
Phase 2/3NPC, HNSCC, Recurrence, MetastasisNot yet recruiting
Est. primary completion 2028-01-01 · NCT06719479 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (5)
Phase 2Osteosarcoma, MetastasisRecruiting
Est. primary completion 2028-03 · NCT07477457 · CT.gov ↗
What to watch
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
Phase 2Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-03-01 · NCT04747912 · CT.gov ↗
What to watch
Phase 1Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia …Recruiting
Est. primary completion 2028-03-31 · NCT06247787 · CT.gov ↗
What to watch
Phase 2Down Syndrome, Acute Lymphoblastic Leukemia, Childhood CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT03286634 · CT.gov ↗
What to watch
April 2028 (1)
Phase 1Primary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2028-04-28 · NCT06541665 · CT.gov ↗
What to watch
May 2028 (3)
Phase 2Acute Lymphoblastic Leukemia, Lymphoblastic LymphomaRecruiting
Est. primary completion 2028-05 · NCT06533748 · CT.gov ↗
What to watch
Phase 2Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Not yet recruiting
Est. primary completion 2028-05-31 · NCT07643103 · CT.gov ↗
What to watch
Phase 2Non-hodgkin LymphomaRecruiting
Est. primary completion 2028-05-31 · NCT05998642 · CT.gov ↗
What to watch
June 2028 (5)
Phase 2Acute Myeloid Leukemia in ChildrenRecruiting
Est. primary completion 2028-06 · NCT06262438 · CT.gov ↗
What to watch
Phase 2/3Childhood EpendymomaRecruiting
Est. primary completion 2028-06 · NCT02265770 · CT.gov ↗
What to watch
Phase 3Primary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2028-06 · NCT04931368 · CT.gov ↗
What to watch
Phase 3Uncontrolled GoutRecruiting
Est. primary completion 2028-06-18 · NCT07388498 · CT.gov ↗
What to watch
Phase 2Down Syndrome, Recurrent B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-06-30 · NCT04546399 · CT.gov ↗
What to watch
July 2028 (4)
Phase 1Muscle Invasive Bladder Urothelial CarcinomaEnrolling by invitation
Est. primary completion 2028-07-01 · NCT06204614 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Active not recruiting
Est. primary completion 2028-07-01 · NCT04530565 · CT.gov ↗
What to watch
Phase 1Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated …Recruiting
Est. primary completion 2028-07-02 · NCT05292664 · CT.gov ↗
What to watch
Phase 3Acute Lymphoblastic Leukemia, PediatricRecruiting
Est. primary completion 2028-07-14 · NCT03643276 · CT.gov ↗
What to watch
August 2028 (3)
Phase 2Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative DisordersRecruiting
Est. primary completion 2028-08 · NCT06265584 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System Lymphoma, Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-08 · NCT07764601 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Bladder CancerActive not recruiting
Est. primary completion 2028-08-31 · NCT05137262 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2/3Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-09-30 · NCT07185373 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine, Doxorubicin, Cisplatin, GemcitabineRecruiting
Est. primary completion 2028-10-31 · NCT06960577 · CT.gov ↗
What to watch
December 2028 (9)
Phase 1/2Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
Phase 2Osteosarcoma in Children, Osteosarcoma in Adolescents and Young AdultsRecruiting
Est. primary completion 2028-12 · NCT07560826 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)Recruiting
Est. primary completion 2028-12-31 · NCT07410520 · CT.gov ↗
What to watch
Phase 2Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2028-12-31 · NCT03779854 · CT.gov ↗
What to watch
Phase 2Acute Lymphoblastic LeukemiaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07301138 · CT.gov ↗
What to watch
Phase 2Central Nervous System Lymphoma, Secondary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2028-12-31 · NCT03964090 · CT.gov ↗
What to watch
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06317662 · CT.gov ↗
What to watch
2029 (8)
March 2029 (2)
May 2029 (2)
June 2029 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06-30 · NCT04293562 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Metastatic Oral Cavity Carcinoma, Recurrent Oral Cavity Carcinoma, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Head and Neck Cancer …Recruiting
Est. primary completion 2029-08-05 · NCT06997068 · CT.gov ↗
What to watch
2030 (10)
March 2030 (1)
Phase 2B Lymphoblastic LeukemiaRecruiting
Est. primary completion 2030-03 · NCT06336395 · CT.gov ↗
What to watch
April 2030 (2)
June 2030 (2)
July 2030 (1)
Phase 2Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Negative Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), LeukemiaRecruiting
Est. primary completion 2030-07-31 · NCT07227584 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Adenocarcinoma of the Breast, Breast Cancer, Triple Negative Breast CancerRecruiting
Est. primary completion 2030-08-11 · NCT07768436 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary MyelofibrosisRecruiting
Est. primary completion 2030-09-01 · NCT07228624 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic SyndromeRecruiting
Est. primary completion 2030-11-22 · NCT06128070 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2030-12-01 · NCT06124157 · CT.gov ↗
What to watch
2031 (4)
January 2031 (1)
Phase 3Graft-versus-host Disease (GVHD)Recruiting
Est. primary completion 2031-01-17 · NCT06615050 · CT.gov ↗
What to watch
April 2031 (1)
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …Not yet recruiting
Est. primary completion 2031-04-16 · NCT07636564 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2Osteosarcoma, Ewing SarcomaRecruiting
Est. primary completion 2031-06-01 · NCT07321912 · CT.gov ↗
What to watch
December 2031 (1)
Phase 3Extranodal NK/T-cell LymphomaRecruiting
Est. primary completion 2031-12-31 · NCT07678229 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
Phase 3B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia …Recruiting
Est. primary completion 2032-03-31 · NCT03959085 · CT.gov ↗
What to watch
2033 (3)
September 2033 (1)
Phase 1/2Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive …Recruiting
Est. primary completion 2033-09-19 · NCT07387926 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2/3Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma …Not yet recruiting
Est. primary completion 2033-11-01 · NCT07724457 · CT.gov ↗
What to watch
December 2033 (1)
Phase 2Lymphoblastic Leukemia in ChildrenRecruiting
Est. primary completion 2033-12-31 · NCT06099366 · CT.gov ↗
What to watch
2034 (2)
2035 (2)
July 2035 (1)
Phase 2MedulloblastomaRecruiting
Est. primary completion 2035-07 · NCT05535166 · CT.gov ↗
What to watch
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruiting
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.